Is It Safe to Take Canagliflozin and Rifampin Together?

Canagliflozin and rifampin should not be used together without careful monitoring and likely dose adjustment. Rifampin is a potent inducer of the UGT1A9 enzyme system, which is responsible for metabolizing canagliflozin. This induction significantly reduces canagliflozin blood levels, potentially compromising glycemic control in patients with type 2 diabetes. The FDA classifies this interaction as moderate severity, meaning clinical outcomes are possible and intervention is necessary.

What the FDA Says

The FDA labeling for canagliflozin (INVOKANA) explicitly warns that UGT enzyme inducers, including rifampin, may decrease canagliflozin exposure and reduce its effectiveness. The prescribing information states that dosage adjustment may be required when these agents are used concomitantly. This guidance reflects pharmacokinetic data from drug interaction studies showing that rifampin co-administration substantially lowers canagliflozin plasma concentrations.

The interaction is classified as moderate rather than severe because alternative antidiabetic agents and dosing strategies exist. However, this does not diminish the clinical significance—patients on this combination face a real risk of inadequate glycemic control, which can lead to hyperglycemic events, DKA (diabetic ketoacidosis), and progression of microvascular complications if not properly managed.

How This Interaction Works: The UGT Enzyme Induction Mechanism

Canagliflozin is primarily eliminated through hepatic metabolism via glucuronidation, catalyzed by the UDP-glucuronosyltransferase (UGT) enzyme family, particularly UGT1A9. Unlike cytochrome P450-dependent metabolism, which is often the focus of drug interaction education, UGT-mediated glucuronidation represents a major phase II metabolic pathway for many drugs, including SGLT2 inhibitors, NSAIDs, statins, and antimicrobials.

Rifampin is one of the most powerful and clinically relevant UGT inducers known. When a patient initiates rifampin therapy, the drug enters hepatocytes and binds to the pregnane X receptor (PXR), a nuclear receptor that acts as a xenobiotic sensor. This PXR activation increases transcription of genes encoding multiple drug-metabolizing enzymes, including UGT1A9, UGT1A1, UGT2B7, and CYP3A4. Within 3 to 5 days of rifampin initiation, UGT enzyme expression increases substantially, sometimes by 3- to 5-fold or more.

For canagliflozin specifically, pharmacokinetic studies show that rifampin co-administration reduces canagliflozin area under the concentration-time curve (AUC) by approximately 40 to 50%, and reduces peak plasma concentration (Cmax) by similar margins. This substantial reduction in exposure directly correlates with reduced pharmacodynamic effect—lower canagliflozin levels produce less SGLT2 inhibition, meaning less urinary glucose excretion and diminished glycemic efficacy.

The clinical consequence is predictable: a patient whose diabetes was well controlled on a standard canagliflozin dose may experience hyperglycemia when rifampin is added, even though the canagliflozin dose has not changed. Fasting and postprandial glucose levels may rise, HbA1c may increase over weeks, and the patient may become symptomatic (polyuria, polydipsia, fatigue) or develop acute hyperglycemic complications.

Who Is Most at Risk

Certain patient populations face heightened risk from this interaction and warrant especially close monitoring:

• Patients with tuberculosis and type 2 diabetes: This is the most common real-world scenario. Tuberculosis (TB) is a global health problem, and many TB patients have concurrent type 2 diabetes (estimated 15–20% of TB cases). Rifampin is a cornerstone of TB therapy, appearing in standard first-line regimens. These patients require both medications for optimal outcomes.
• Older adults (age ≥65 years): Reduced hepatic blood flow and declining UGT enzyme activity with age can complicate the interaction. While rifampin is still a powerful inducer, older patients may have narrower margins for dose adjustment and greater sensitivity to hyperglycemia.
• Patients with advanced chronic kidney disease or end-stage renal disease: Although canagliflozin is metabolized hepatically (not renally), patients with severe renal impairment often have comorbid liver disease or reduced metabolic capacity. Additionally, canagliflozin is less effective in advanced CKD, and the additional hit from rifampin-induced metabolism may push glycemic control further into inadequate range.
• Patients on marginal canagliflozin dosing: A patient already at the lower end of efficacy (e.g., on 100 mg daily rather than 300 mg daily due to tolerability or contraindications) will be affected more severely by a 40–50% reduction in drug exposure than a patient on standard dosing.
• Patients with brittle diabetes or poor glycemic reserve: Those with limited ability to tolerate glucose fluctuations, or those with recurrent DKA history, are at higher risk of serious outcomes if canagliflozin efficacy wanes unexpectedly.

Clinical Scenario 1: TB-Diabetes Co-Infection

A 52-year-old male with a 10-year history of type 2 diabetes, well controlled on canagliflozin 300 mg daily and metformin 2000 mg daily, presents with a 4-week productive cough, night sweats, and weight loss. Chest X-ray and sputum smears confirm active pulmonary tuberculosis. The TB specialist initiates rifampin-isoniazid-pyrazinamide-ethambutol quadruple therapy. The patient's family medicine physician and the TB specialist do not coordinate medication reviews.

Over the following 2 weeks, the patient develops increased thirst and urination. His home glucose monitor readings, previously averaging 110–130 mg/dL fasting, now read 180–220 mg/dL. He attributes this to stress from the TB diagnosis. By week 4, he develops signs of diabetic ketoacidosis: malaise, tachypnea, fruity breath odor, and a venous pH of 7.28 with bicarbonate of 18 mEq/L. He requires hospitalization for DKA management.

What went wrong: Rifampin induction of UGT1A9 reduced canagliflozin exposure by approximately 45%, effectively reducing the drug's efficacy by nearly half. The patient's diabetes control deteriorated silently over days. Because no one reviewed the new drug interaction, the hyperglycemia was neither anticipated nor addressed proactively. SGLT2 inhibitors carry a known risk of euglycemic DKA (DKA at normal or only mildly elevated glucose), which may have contributed to the severity of presentation.

How to prevent this: When TB therapy is initiated in a diabetic patient, the prescriber should immediately increase canagliflozin to the maximum approved dose (300 mg daily if not already on it, or consider alternative strategies if already maxed). Additionally, the patient should self-monitor blood glucose more frequently (at least twice daily), have HbA1c checked at 4–6 weeks rather than the standard 3-month interval, and maintain close contact with both TB and diabetes providers. Some clinicians might elect to switch to a different antidiabetic agent not affected by UGT induction, such as insulin or a GLP-1 agonist.

Clinical Scenario 2: Dosing Miscalculation in Polypharmacy

A 68-year-old woman with type 2 diabetes on canagliflozin 100 mg daily (reduced dose due to history of genital mycotic infections) and a recent diagnosis of non-tuberculosis mycobacterial (NTM) lung infection is prescribed a prolonged rifampin-containing regimen. Her renal function is stable (eGFR 58 mL/min/1.73m²). Her diabetes provider does not adjust her canagliflozin dose, reasoning that 100 mg is already a lower dose and increasing it might exacerbate urinary tract infections.

Within 3 weeks, her glycemic markers deteriorate: fasting glucose 145–165 mg/dL, random glucose checks frequently in the 200+ range. Her HbA1c, which was 6.8% three months prior, begins to trend upward. She develops mild polyuria and feels fatigued. Her provider attributes this to the NTM infection rather than medication interaction.

What went wrong: The reasoning to avoid a dose increase was based on tolerability concerns, not pharmacokinetic data. However, when rifampin is added, the already-marginal 100 mg dose becomes even less effective due to UGT induction. The patient needed an increase in canagliflozin, an alternative agent, or a more intensive glucose-monitoring strategy.

How to prevent this: When facing marginal dosing of canagliflozin, providers should weigh tolerability risks against efficacy risks. If canagliflozin induction by a UGT enzyme inducer is anticipated, switching to an alternative antidiabetic agent (e.g., SGLT2 inhibitor not predominantly metabolized by UGT, GLP-1 agonist, basal insulin, or intensified metformin) is often preferable to a dose increase that may not sufficiently compensate for the interaction.

What to Do: Management Strategies

For Healthcare Providers:

1. Anticipate the interaction before it occurs. When rifampin is prescribed to a patient on canagliflozin, document this planned interaction in the medical record and establish a management plan before the patient starts rifampin.
2. Increase canagliflozin to the maximum tolerated dose. If the patient is not already on canagliflozin 300 mg daily, consider increasing to 300 mg daily at the time rifampin is initiated. This provides some buffer against the 40–50% reduction in exposure. Monitor for tolerability (volume depletion, genital infections, euglycemic DKA).
3. Consider alternative antidiabetic agents. If dose escalation is not feasible or not tolerated, switching to a medication not affected by UGT induction is often the best option. GLP-1 receptor agonists (e.g., semaglutide, dulaglutide), SGLT2 inhibitors less dependent on UGT (though all are affected to some degree), sulfonylureas, DPP-4 inhibitors, or insulin are alternatives. Consult with endocrinology if uncertain.
4. Implement intensive glucose monitoring. Advise the patient to check blood glucose at least twice daily (fasting and before dinner, at minimum). Consider continuous glucose monitoring (CGM) if available and patient is willing. Establish a glucose target range and an action plan for hyperglycemia (e.g., when to contact the provider).
5. Check HbA1c at 4–6 weeks, not the standard 12 weeks. UGT induction reaches steady state within 5–7 days of rifampin initiation. Any deterioration in glycemic control should be apparent by 4 weeks. If HbA1c rises above baseline, adjust therapy immediately rather than waiting for routine follow-up.
6. Screen for acute complications. Educate the patient on signs of hyperglycemia and, critically, signs of euglycemic DKA (nausea, vomiting, abdominal pain, dyspnea, altered mental status) even if glucose is not dramatically elevated. This is important because SGLT2 inhibitors can precipitate DKA at glucose levels <250 mg/dL.

For Patients:

• Inform your doctor and pharmacist immediately if rifampin or any other tuberculosis medication is prescribed.
• Do not stop canagliflozin or change your dose without consulting your diabetes provider.
• Perform home glucose monitoring as instructed—this is critical to detect loss of glycemic control early.
• Keep scheduled appointments for HbA1c testing, and ask your provider to schedule it sooner than usual (4–6 weeks rather than 3 months) when starting rifampin.
• Drink adequate fluids to avoid dehydration, especially important with SGLT2 inhibitors.
• Report new or worsening thirst, frequent urination, fatigue, or any signs of infection to your provider promptly.

When to Call Your Doctor or Pharmacist

Seek immediate medical attention or call emergency services if you experience:

• Nausea, vomiting, or persistent abdominal pain (possible DKA)
• Rapid or difficult breathing
• Confusion or altered mental status
• Blood glucose persistently >250 mg/dL despite home management
• Signs of urinary tract infection (dysuria, frequency, urgency) or severe genital infection
• Severe dehydration symptoms (extreme thirst, dizziness, syncope)

Contact your provider (within 24 hours) if you notice:

• Fasting or random blood glucose consistently higher than usual (e.g., 20+ mg/dL above your baseline)
• Increased thirst or urination not explained by rifampin-related illness symptoms
• Fatigue or malaise beyond what you'd expect from TB treatment alone
• Questions about dose adjustments or medication timing

Key Takeaways

• Rifampin induces UGT1A9 glucuronidation, reducing canagliflozin exposure by 40–50% and significantly impairing its glycemic efficacy. This is a moderate-severity interaction requiring active management, not passive observation.
• Patients most at risk include those with TB-diabetes co-infection, older adults, those with advanced CKD, and patients already on marginal canagliflozin dosing. Early identification of these patients enables proactive intervention.
• Management options include dose escalation to 300 mg daily, switching to an alternative antidiabetic agent not affected by UGT induction, or intensive glucose monitoring with earlier HbA1c reassessment. No single strategy is best for all patients; individualization based on comorbidities and tolerability is essential.
• Providers should anticipate this interaction before rifampin is started, document the plan, and establish a glucose-monitoring protocol. Coordination between TB and diabetes providers is critical to prevent treatment failures and complications like DKA.
• Patients on this combination must be educated on the risk of hyperglycemia and euglycemic DKA, and must commit to frequent self-monitoring and close follow-up. Silent loss of glycemic control is a serious risk with this interaction.

Sources

• FDA Drug Approval Information via OpenFDA
• NCBI PubChem: Canagliflozin
• NCBI PubChem: Rifampin
• National Library of Medicine (NIH)
• FDA Prescribing Information: INVOKANA (canagliflozin) package insert. Available via FDA.gov and major pharmacy databases.
• FDA Prescribing Information: Rifampin (rifampicin) package insert and tuberculosis drug information resources.
• UpToDate: Drug Interactions and Enzyme Induction (subscription resource; cited for clinical context)

If you are taking canagliflozin and rifampin—or any combination of medications—visit checkdruginteractions.com to run a comprehensive medication interaction check powered by over 250,000 FDA drug labels. Our database identifies moderate and severe interactions like this one, helping you and your healthcare team make informed decisions about your medications. Enter all your current prescriptions, over-the-counter drugs, and supplements to see a complete safety profile—it takes just minutes and could prevent a serious adverse event.